Meta Biomed Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	101,187	102,951	94,036	83,101	68,942	58,780
Other Revenue	0	-	-	-0	-0	-0
Revenue	101,187	102,951	94,036	83,101	68,942	58,780
Revenue Growth	1.82%	9.48%	13.16%	20.54%	17.29%	30.63%
Cost of Revenue	48,009	49,358	46,675	45,110	39,746	33,778
Gross Profit	53,178	53,593	47,361	37,990	29,196	25,003
Selling, General & Admin	27,488	26,272	23,143	21,651	18,682	15,455
Research & Development	5,702	4,967	5,140	4,538	4,343	3,339
Operating Expenses	34,265	32,399	30,139	27,388	23,831	19,741
Operating Income	18,913	21,194	17,222	10,602	5,365	5,261
Interest Expense	-2,058	-2,846	-3,742	-2,315	-1,390	-1,145
Interest & Investment Income	894.89	1,123	635.32	375.03	206.78	29.82
Earnings From Equity Investments	-303.12	640.87	-	-	-	537.62
Currency Exchange Gain (Loss)	3,668	-427.77	3,453	232.84	-523.93	1,509
Other Non Operating Income (Expenses)	-1,311	-6,631	4,212	-861.26	-734.59	1,171
EBT Excluding Unusual Items	19,804	13,053	21,781	8,034	2,923	7,364
Gain (Loss) on Sale of Investments	1,500	300.42	1,530	773.17	426.74	-39.83
Gain (Loss) on Sale of Assets	9.17	-52.74	-13.88	12.62	47.62	801.18
Asset Writedown	-707.61	-707.61	-	-1,015	-487.37	-541.23
Other Unusual Items	12.58	-	-	-	-	-
Pretax Income	20,618	12,593	23,297	7,805	2,910	7,584
Income Tax Expense	3,920	1,822	1,146	-2,223	64.5	-1,938
Earnings From Continuing Operations	16,699	10,772	22,150	10,027	2,846	9,521
Earnings From Discontinued Operations	-	-	174.43	-211.99	754.18	140.51
Net Income to Company	16,699	10,772	22,325	9,815	3,600	9,662
Minority Interest in Earnings	294.36	216.8	77.62	265	-972.22	-140.45
Net Income	16,993	10,988	22,402	10,080	2,628	9,522
Net Income to Common	16,993	10,988	22,402	10,080	2,628	9,522
Net Income Growth	-3.41%	-50.95%	122.24%	283.61%	-72.40%	-
Shares Outstanding (Basic)	27	25	23	23	23	23
Shares Outstanding (Diluted)	29	25	27	23	23	23
Shares Change	24.05%	-7.40%	18.55%	-0.06%	-0.07%	-0.61%
EPS (Basic)	631.15	437.65	979.63	440.75	114.82	415.77
EPS (Diluted)	591.95	437.65	655.73	440.75	114.82	415.77
EPS Growth	-4.50%	-33.26%	48.78%	283.85%	-72.38%	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	100.64	-471.17	11,719	-1,271	-6,236	9,069
Free Cash Flow Per Share	3.50	-18.77	432.22	-55.59	-272.48	396.00
Dividend Per Share	105.000	105.000	30.000	20.000	20.000	20.000
Dividend Growth	250.00%	250.00%	50.00%	0%	0%	100.00%
Gross Margin	52.55%	52.06%	50.36%	45.72%	42.35%	42.54%
Operating Margin	18.69%	20.59%	18.31%	12.76%	7.78%	8.95%
Profit Margin	16.79%	10.67%	23.82%	12.13%	3.81%	16.20%
Free Cash Flow Margin	0.10%	-0.46%	12.46%	-1.53%	-9.04%	15.43%
EBITDA	24,855	26,694	22,203	14,825	9,225	8,832
EBITDA Margin	24.56%	25.93%	23.61%	17.84%	13.38%	15.02%
D&A For EBITDA	5,942	5,499	4,981	4,223	3,860	3,571
EBIT	18,913	21,194	17,222	10,602	5,365	5,261
EBIT Margin	18.69%	20.59%	18.31%	12.76%	7.78%	8.95%
Effective Tax Rate	19.01%	14.47%	4.92%	-	2.22%	-
Advertising Expenses	-	387.86	298.35	151.08	230.86	245.85